cyclosporine
Phase 3- Indications
- Ulcerative colitis
Company intelligence / Profile preview
Sigmoid Pharma
Dublin, Leinster, Irelandsigmoidpharma.com ↗
- Ownership
- Private
- Employees
- ~6
- Development stage
- Phase 3
01
Overview
Sigmoid Pharma develops innovative oral drug delivery systems using its proprietary SmPill® platform, focusing on gastrointestinal and immunological diseases. Its lead asset, CyCol®, a colon-targeted cyclosporine formulation, has completed Phase II trials in moderate-severe ulcerative colitis with plans to advance to Phase III. The company also holds an FDA Orphan Designation for a product targeting graft-versus-host disease. The SmPill technology enables improved safety/efficacy profiles by delivering drugs directly to the site of action while minimizing systemic exposure.
- Therapeutic areas
- GastroenterologyImmunologyNeurology
- Modalities
- Small molecules (e.g., cyclosporine)Peptides (oral delivery focus)Vaccines (oral delivery focus)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Collaborations with medical centers of excellence and international pharmaceutical/biotech institutions are referenced but not named specifically.
Beyond the preview
Go deeper on Sigmoid Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sigmoid Pharma.